Alnylam Pharmaceuticals' Gains from Investment Securities rose 98.14% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 50.30%. This contributed to the annual value of $14.4 million for FY2024, which is 138.50% up from last year.
Per Alnylam Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $14.4 million for FY2024, which was up 138.50% from $6.0 million recorded in FY2023.
Over the past 5 years, Alnylam Pharmaceuticals' Gains from Investment Securities peaked at $34.4 million during FY2020, and registered a low of $4.2 million during FY2021.
For the 3-year period, Alnylam Pharmaceuticals' Gains from Investment Securities averaged around $8.4 million, with its median value being $6.0 million (2023).
Per our database at Business Quant, Alnylam Pharmaceuticals' Gains from Investment Securities skyrocketed by 391.93% in 2020 and then tumbled by 87.81% in 2021.
Over the past 5 years, Alnylam Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $34.4 million in 2020, then crashed by 87.81% to $4.2 million in 2021, then increased by 11.82% to $4.7 million in 2022, then increased by 28.27% to $6.0 million in 2023, then soared by 138.50% to $14.4 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value